CAR-T Therapy Market Analysis, Size, Share, Trends, and Forecast by 2031

The CAR-T Therapy Market size is expected to reach US$ 31.52 Billion by 2031. The market is anticipated to register a CAGR of 34.8% during 2025-2031.

The report is segmented by Targeted Antigen (CD 19,BCMA,HER2,GD2,CD 20,CD22,CD30,CD33,HER1 and Others). Further, the market is segmented on the basis of Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer and Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report CAR-T Therapy Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

CAR-T Therapy Market Segmentation Targeted Antigen

1. CD 19
2. BCMA
3. HER2
4. GD2
5. CD 20
6. CD22
7. CD30
8. CD33
9. HER1 and Others

Therapeutic Application

1. Acute Lymphocytic Leukemia
2. Chronic Lymphocytic Leukemia
3. Diffuse Large B-Cell Lymphoma
4. Follicular Lymphoma
5. Multiple Myeloma
6. Glioblastoma
7. Sarcoma
8. Neuroblastoma
9. Acute Myeloid Leukemia
10. Breast Cancer
11. Pancreatic Cancer
12. Hepatocellular Carcinoma
13. Colorectal Cancer and Others

CAR-T Therapy Market: Strategic Insights

CAR-T Therapy Market Growth Drivers

1. Incidence of Cancer: According to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. According to the International Agency of Research on Cancer, in 2040, 30.3 million new cases will be added to the global cancer burden. Chimeric antigen receptor (CAR) T-cell therapies can potentially treat new type of cancer treatment that uses the immune system to fight cancer. CAR T involves genetically engineering T cells to express a chimeric antigen receptor targeting a specific tumor antigen. Thus, the growing burden of cancer is driving the CAR-T therapy market.
   
2. CAR-T approvals: Globally, cell therapies are widely adopted owing to the availability FDA approved products. In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 1 month of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.
   
3. CAR-T cell manufacturing: Latest developments in CAR-T cell manufacturing are efficiency-driven, scalable, and cost-effective. Reduced human error to improve throughput is a result of automation at the stage of cell processing, therefore, having faster production cycles. Modular facilities have the ability to be flexible and scaled rapidly as needed to meet demand without large capital investments.

CAR-T Therapy Market Future Trends

1. Rising Number of CAR T-Cell Therapies in Clinical Trials: The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain. JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.
   
2. Focus on Safety: Accordingly, ensuring confidence in such novel treatments also requires that improvements be made to the outcomes from CAR-T therapy by focusing on safety. Research is thus conducted on predictive measures, prevention, and management of one of the common side effects associated with CAR-T treatment, CRS. This includes improvement in protocols concerning the selection and monitoring of patients.
   
3. Biomarker Development: Biomarkers for CAR-T therapy research should be regarded as an important factor that tends to improve the aspects of patient selection and treatment outcomes. This approach aids in knowing the effectiveness of CAR-T therapies and bringing in provisions for the adjustment in a timely manner as deemed necessary. The unification of academia, industry, and clinical research is important for helping in advancing the discovery and validation of new biomarkers that bring innovation into the field of CAR-T therapy.

CAR-T Therapy Market Opportunities

1. Growing Investment in CAR-T Therapy: Companies operating in the T: cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investment, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. In August 2023, Astellas invested US$ 50 million in PoseidaReport Scope

   CAR-T Therapy Market Regional Insights

   The regional trends and factors influencing the CAR-T Therapy Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses CAR-T Therapy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

   CAR-T Therapy Market Report Scope

   By Therapeutic Application

   • Acute Lymphocytic Leukemia
   • Chronic Lymphocytic Leukemia
   • Diffuse Large B-Cell Lymphoma
   • Follicular Lymphoma
   • Multiple Myeloma
   • Glioblastoma
   • Sarcoma
   • Neuroblastoma
   • Acute Myeloid Leukemia
   • Breast Cancer
   • Pancreatic Cancer
   • Hepatocellular Carcinoma
   • Colorectal Cancer and Others

   Europe

   • UK
   • Germany
   • France
   • Russia
   • Italy
   • Rest of Europe

   Asia-Pacific

   • China
   • India
   • Japan
   • Australia
   • Rest of Asia-Pacific

   South and Central America

   • Brazil
   • Argentina
   • Rest of South and Central America

   Middle East and Africa

   • South Africa
   • Saudi Arabia
   • UAE
   • Rest of Middle East and Africa

   Report Attribute	Details
   Market size in 2024	US$ XX Billion
   Market Size by 2031	US$ 31.52 Billion
   Global CAGR (2025 - 2031)	34.8%
   Historical Data	2021-2023
   Forecast period	2025-2031
   Segments Covered	By Targeted Antigen CD 19 BCMA HER2 GD2 CD 20 CD22 CD30 CD33 HER1 and Others
   Regions and Countries Covered	North America US Canada Mexico
   Market leaders and key company profiles	Novartis International AG Kite Pharma, Inc. (Gilead Sciences, Inc.) Juno Therapeutics (Celgene Corporation) Bluebird Bio, Inc. (Celgene Corporation) Sorrento Therapeutics Inc. Mustang Bio, Inc Aurora Biopharma Inc. Legend Biotech (Genscript Biotech Corporation) Pfizer, Inc.

   
   

   CAR-T Therapy Market Players Density: Understanding Its Impact on Business Dynamics

   The CAR-T Therapy Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

   
   
   
   • Get the CAR-T Therapy Market top key players overview
   Free Sample PDF